6-ethyl-3H-indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-ethyl-3H-indole
• 化学式: C₁₀H₁₁N
• 分子量: 145.2
• InChiKey: HTIOWBCIWUJLNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：EP3838897A2

  公开（公告）日：2021-06-23

  Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.

  本发明提供了一种如式（I）所示的对蛋白激酶活性具有抑制作用的（杂）芳酰胺化合物、其药学上可接受的盐、立体异构体、溶液或水合物、包含该化合物或其衍生物的药物组合物以及制备该化合物的方法。该化合物可用作蛋白激酶的不可逆抑制剂，用于制备包含抗肿瘤药物的多种药物。
• 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME
  申请人：Trevena, Inc.

  公开号：EP4086249A2

  公开（公告）日：2022-11-09

  The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

  本发明的实施方案部分涉及用于调节δ阿片受体活性的化合物或其药学上可接受的盐，或其药物组合物，偏向和/或不偏向，和/或用于治疗疼痛、偏头痛、头痛、抑郁症、帕金森病、焦虑和/或膀胱过度活动症，以及本文所述的其他疾病和病症或其任意组合的方法。
• [EN] 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME<br/>[FR] AZA-HÉTÉROCYCLIQUE À 6 ÉLÉMENTS CONTENANT DES COMPOSÉS MODULATEURS DE RÉCEPTEURS OPIOÏDES DELTA, ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：TREVENA INC

  公开号：WO2017040545A1

  公开（公告）日：2017-03-09

  The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.